Masimo IP Verdict A Timely Warning For All Device Inventors, Says Counsel
Executive Summary
Masimo Corp. has spent much time and effort over the last decade and a half addressing patent and IP issues surrounding its pulse oximetry technology – and it’s not over yet: an ongoing case with Philips and a future case with Mindray Medical will keep the company busy for some time to come. But for Masimo’s legal counsel, these cases underline the vital need for appropriate protection of inventions – and not just for the company’s benefit.
You may also be interested in...
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.
An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024
Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.